Cargando…

Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?

Detalles Bibliográficos
Autores principales:	Leucht, Stefan, Huhn, Maximilian, Davis, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563551/ https://www.ncbi.nlm.nih.gov/pubmed/34586466 http://dx.doi.org/10.1007/s00406-021-01335-y

Ejemplares similares

Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2022)

Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
por: Huhn, Maximilian, et al.
Publicado: (2022)

T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS
por: Susanne Neumeier, Maria, et al.
Publicado: (2020)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Has Research Informed Us on the Practical Drug Treatment of Schizophrenia?
por: Davis, John M., et al.
Publicado: (2008)

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
por: Huhn, Maximilian, et al.
Publicado: (2020)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
por: Huhn, Maximilian, et al.
Publicado: (2019)

S235. MAINTENANCE TREATMENT WITH ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA – SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

Commentary on strategies for switching antipsychotics
por: Davis, John M, et al.
Publicado: (2008)

O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
por: Leucht, Stefan, et al.
Publicado: (2018)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia
por: Fujimaki, Koichiro, et al.
Publicado: (2012)

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
por: Ruberg, Stephen J, et al.
Publicado: (2011)

Where are lithium carbonate, typical antipsychotics, imipramine, and some other efficacious medications?
por: Nardi, Antonio E., et al.
Publicado: (2020)

Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials
por: Siafis, Spyridon, et al.
Publicado: (2023)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review
por: Tajika, Aran, et al.
Publicado: (2023)

Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment
por: Güneş, Mehmet, et al.
Publicado: (2016)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics
por: Nagamine, Takahiko
Publicado: (2008)

Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects
por: Choi, Kwang H, et al.
Publicado: (2009)

Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand
por: Boonlue, Tuanthon, et al.
Publicado: (2016)

Adherence to Typical Antipsychotics among Patients with Schizophrenia in Uganda: A Cross-Sectional Study
por: Kule, Moses, et al.
Publicado: (2023)

T6. SECOND GENERATION ANTIPSYCHOTIC DRUGS AND MORTALITY: A META-ANALYSIS OF PLACEBO-CONTROLLED RANDOMISED CONTROLLED TRIALS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
por: Karthik, M. S., et al.
Publicado: (2014)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study
por: De Hert, Marc, et al.
Publicado: (2011)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu, Chengcheng, et al.
Publicado: (2020)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis
por: Mousavi, Seyed Ghafur, et al.
Publicado: (2013)

Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials
por: Schneider-Thoma, Johannes, et al.
Publicado: (2021)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_phsij5o2v9pbgqqoga98fa181b